A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

Dapagliflozin helped people reduce fat levels in their liver and avoid liver scarring that comes with the condition, which ...

A diabetes drug, dapagliflozin, has shown promise in treating fatty liver disease by reducing liver fat and scarring, ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

A new study reveals that dapagliflozin, a common diabetes medication, could significantly improve conditions like metabolic ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra), said accompanying editorial authors Leila Haddad, MD, and Sebastián ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...

Reviewing the amendment protocol of the AstraZeneca's fixed dose combination (FDC) Zibotentan plus Dapagliflozin, the Subject ...

ANSWER: Both prediabetes and diabetes are metabolic abnormalities in which the body cannot use sugar properly. There are ...

In people with diabetes, Farxiga drops A1C levels by roughly 0.6%, which is not a huge amount compared to other diabetes ...